Erasca, Inc. - Common Stock (ERAS)

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (NYSE: ABBV) was in advanced discussions

ERAS stock results show that Erasca missed analyst estimates for earnings per share the second quarter of 2024.

ERAS stock results show that Erasca missed analyst estimates for earnings per share the first quarter of 2024.

ERAS stock results show that Erasca beat analyst estimates for earnings per share the fourth quarter of 2023.

Consider the pros and cons of buying these penny stocks, which can deliver risk-adjusted returns to investors' portfolios.

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

The Dow Jones closed lower by around 70 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.

U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.